You just read:

PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At ASH Annual Meeting

News provided by

CTI BioPharma Corp.

06 Dec, 2016, 10:30 ET